{"id":"https://openalex.org/W2471323617","doi":"https://doi.org/10.1182/blood.v124.21.4687.4687","title":"Preliminary Results of a Phase 1b Study (GP28331) Combining GDC-0199 (ABT-199) and Obinutuzumab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia","display_name":"Preliminary Results of a Phase 1b Study (GP28331) Combining GDC-0199 (ABT-199) and Obinutuzumab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia","publication_year":2014,"publication_date":"2014-12-06","ids":{"openalex":"https://openalex.org/W2471323617","doi":"https://doi.org/10.1182/blood.v124.21.4687.4687","mag":"2471323617"},"language":"en","primary_location":{"id":"doi:10.1182/blood.v124.21.4687.4687","doi":"https://doi.org/10.1182/blood.v124.21.4687.4687","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v124.21.4687.4687","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5000959540","display_name":"Ian W. Flinn","orcid":"https://orcid.org/0000-0001-6724-290X","observed_orcids":["https://orcid.org/0000-0001-6724-290X"]},"institutions":[{"id":"https://openalex.org/I4210100810","display_name":"Sarah Cannon","ror":"https://ror.org/014t21j89","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210100810"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ian Flinn","raw_affiliation_strings":["Sarah Cannon Research Institute, Nashville, TN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sarah Cannon Research Institute, Nashville, TN","institution_ids":["https://openalex.org/I4210100810"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045191576","display_name":"Mark W. Brunvand","orcid":"https://orcid.org/0000-0003-1229-2699","observed_orcids":["https://orcid.org/0000-0003-1229-2699"]},"institutions":[{"id":"https://openalex.org/I4210134093","display_name":"Colorado Blood Cancer Institute","ror":"https://ror.org/040pncp85","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210134093"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Mark Brunvand","raw_affiliation_strings":["Colorado Blood Cancer Institute, Denver, CO"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Colorado Blood Cancer Institute, Denver, CO","institution_ids":["https://openalex.org/I4210134093"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5081516283","display_name":"Martin J.S. Dyer","orcid":"https://orcid.org/0000-0002-5033-2236","observed_orcids":["https://orcid.org/0000-0002-5033-2236"]},"institutions":[{"id":"https://openalex.org/I153648349","display_name":"University of Leicester","ror":"https://ror.org/04h699437","country_code":"GB","type":"education","lineage":["https://openalex.org/I153648349"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Martin JS Dyer","raw_affiliation_strings":["University of Leicester, Leicester, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Leicester, Leicester, United Kingdom","institution_ids":["https://openalex.org/I153648349"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025096739","display_name":"Peter Hillman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2801331674","display_name":"St James's University Hospital","ror":"https://ror.org/013s89d74","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I2799390153","https://openalex.org/I2801331674"]}],"countries":["GB"],"is_corresponding":true,"raw_author_name":"Peter Hillman","raw_affiliation_strings":["St. James University Hospital, Leeds, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"St. James University Hospital, Leeds, United Kingdom","institution_ids":["https://openalex.org/I2801331674"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102896676","display_name":"Jeffrey Alan Jones","orcid":"https://orcid.org/0000-0001-9557-0820","observed_orcids":["https://orcid.org/0000-0001-9557-0820"]},"institutions":[{"id":"https://openalex.org/I52357470","display_name":"The Ohio State University","ror":"https://ror.org/00rs6vg23","country_code":"US","type":"education","lineage":["https://openalex.org/I52357470"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Jeffrey Jones","raw_affiliation_strings":["Ohio State University School of Medicine, Columbus, OH"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Ohio State University School of Medicine, Columbus, OH","institution_ids":["https://openalex.org/I52357470"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066256806","display_name":"James F. Lymp","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I183934855","display_name":"Genentech","ror":"https://ror.org/04gndp242","country_code":"US","type":"company","lineage":["https://openalex.org/I118019719","https://openalex.org/I129302853","https://openalex.org/I183934855"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"James Lymp","raw_affiliation_strings":["Genentech, Inc., South San Francisco, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Genentech, Inc., South San Francisco, CA","institution_ids":["https://openalex.org/I183934855"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070686562","display_name":"Mostafa Elhamy","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I183934855","display_name":"Genentech","ror":"https://ror.org/04gndp242","country_code":"US","type":"company","lineage":["https://openalex.org/I118019719","https://openalex.org/I129302853","https://openalex.org/I183934855"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Mostafa Elhamy","raw_affiliation_strings":["Genentech, Inc., South San Francisco, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Genentech, Inc., South San Francisco, CA","institution_ids":["https://openalex.org/I183934855"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015475109","display_name":"Gregory Sumpao Vosganian","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I183934855","display_name":"Genentech","ror":"https://ror.org/04gndp242","country_code":"US","type":"company","lineage":["https://openalex.org/I118019719","https://openalex.org/I129302853","https://openalex.org/I183934855"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Gregory Vosganian","raw_affiliation_strings":["Genentech, Inc., South San Francisco, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Genentech, Inc., South San Francisco, CA","institution_ids":["https://openalex.org/I183934855"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101406250","display_name":"Jane Q. Huang","orcid":"https://orcid.org/0009-0004-4549-6625","observed_orcids":["https://orcid.org/0009-0004-4549-6625"]},"institutions":[{"id":"https://openalex.org/I183934855","display_name":"Genentech","ror":"https://ror.org/04gndp242","country_code":"US","type":"company","lineage":["https://openalex.org/I118019719","https://openalex.org/I129302853","https://openalex.org/I183934855"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Jane Huang","raw_affiliation_strings":["Genentech, Inc., South San Francisco, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Genentech, Inc., South San Francisco, CA","institution_ids":["https://openalex.org/I183934855"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5036828560","display_name":"Thomas J. Kipps","orcid":"https://orcid.org/0000-0002-0064-4549","observed_orcids":["https://orcid.org/0000-0002-0064-4549"]},"institutions":[{"id":"https://openalex.org/I36258959","display_name":"University of California San Diego","ror":"https://ror.org/0168r3w48","country_code":"US","type":"education","lineage":["https://openalex.org/I36258959"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Thomas J. Kipps","raw_affiliation_strings":["Univ. of California, San Diego, La Jolla, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Univ. of California, San Diego, La Jolla, CA","institution_ids":["https://openalex.org/I36258959"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":7,"corresponding_author_ids":["https://openalex.org/A5015475109","https://openalex.org/A5025096739","https://openalex.org/A5045191576","https://openalex.org/A5066256806","https://openalex.org/A5070686562","https://openalex.org/A5101406250","https://openalex.org/A5102896676"],"corresponding_institution_ids":["https://openalex.org/I183934855","https://openalex.org/I2801331674","https://openalex.org/I4210134093","https://openalex.org/I52357470"],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":4.9595,"has_fulltext":false,"cited_by_count":26,"citation_normalized_percentile":{"value":0.95909446,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":100},"biblio":{"volume":"124","issue":"21","first_page":"4687","last_page":"4687"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10950","display_name":"Acute Lymphoblastic Leukemia research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/chronic-lymphocytic-leukemia","display_name":"chronic lymphocytic leukemia","score":0.9169999957084656},{"id":"https://openalex.org/keywords/venetoclax","display_name":"venetoclax","score":0.9409999847412109},{"id":"https://openalex.org/keywords/bcl2-inhibitors","display_name":"BCL-2 inhibitor","score":0.8640000224113464},{"id":"https://openalex.org/keywords/obinutuzumab","display_name":"obinutuzumab","score":1.0},{"id":"https://openalex.org/keywords/anti-cd20-monoclonal-antibody","display_name":"anti-CD20 monoclonal antibody","score":0.8740000128746033},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.8700000047683716},{"id":"https://openalex.org/keywords/relapsed-refractory-cll","display_name":"relapsed/refractory CLL","score":0.9269999861717224},{"id":"https://openalex.org/keywords/previously-untreated-cll","display_name":"previously untreated CLL","score":0.9710000157356262},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.8550000190734863},{"id":"https://openalex.org/keywords/safety-and-tolerability","display_name":"safety and tolerability","score":0.8009999990463257},{"id":"https://openalex.org/keywords/tumor-lysis-syndrome","display_name":"tumor lysis syndrome","score":0.7609999775886536},{"id":"https://openalex.org/keywords/dosing-regimen","display_name":"dosing regimen","score":0.5320000052452087},{"id":"https://openalex.org/keywords/drug-synergy","display_name":"drug synergy","score":0.4519999921321869},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.4099999964237213},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.3109999895095825}],"concepts":[{"id":"https://openalex.org/C2777607594","wikidata":"https://www.wikidata.org/wiki/Q389496","display_name":"Obinutuzumab","level":4,"score":0.9365066289901733},{"id":"https://openalex.org/C2777866208","wikidata":"https://www.wikidata.org/wiki/Q415939","display_name":"Chlorambucil","level":4,"score":0.7877072095870972},{"id":"https://openalex.org/C2777938653","wikidata":"https://www.wikidata.org/wiki/Q1088156","display_name":"Chronic lymphocytic leukemia","level":3,"score":0.7241290211677551},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6966836452484131},{"id":"https://openalex.org/C2779263901","wikidata":"https://www.wikidata.org/wiki/Q185916","display_name":"Fludarabine","level":4,"score":0.6893417239189148},{"id":"https://openalex.org/C2779788671","wikidata":"https://www.wikidata.org/wiki/Q998803","display_name":"Tumor lysis syndrome","level":3,"score":0.6887199878692627},{"id":"https://openalex.org/C2779675984","wikidata":"https://www.wikidata.org/wiki/Q23671272","display_name":"Venetoclax","level":4,"score":0.5177280306816101},{"id":"https://openalex.org/C18031839","wikidata":"https://www.wikidata.org/wiki/Q5009796","display_name":"CD20","level":3,"score":0.513307511806488},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.48320019245147705},{"id":"https://openalex.org/C2779015954","wikidata":"https://www.wikidata.org/wiki/Q420164","display_name":"Alemtuzumab","level":3,"score":0.4342738389968872},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.38239794969558716},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.3477534055709839},{"id":"https://openalex.org/C2776755627","wikidata":"https://www.wikidata.org/wiki/Q408524","display_name":"Cyclophosphamide","level":3,"score":0.2574814558029175},{"id":"https://openalex.org/C2911091166","wikidata":"https://www.wikidata.org/wiki/Q106419912","display_name":"Transplantation","level":2,"score":0.23569509387016296},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.18661028146743774},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.1853714883327484}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood.v124.21.4687.4687","doi":"https://doi.org/10.1182/blood.v124.21.4687.4687","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v124.21.4687.4687","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9940000176429749,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2979410532","https://openalex.org/W2980314560","https://openalex.org/W97712808","https://openalex.org/W1981177563","https://openalex.org/W2518387705","https://openalex.org/W1996134582","https://openalex.org/W2342075860","https://openalex.org/W2979462529","https://openalex.org/W4248185195","https://openalex.org/W2763597254"],"abstract_inverted_index":{"Abstract":[0],"Introduction":[1],"Despite":[2,663],"progress":[3],"in":[4,29,85,104,136,140,164,313,322,382,387,398,419,424,456,467,515,521,551,633,690,697,714],"chronic":[5],"lymphocytic":[6],"leukemia":[7],"(CLL)":[8],"treatment,":[9],"new":[10],"therapies":[11,448],"are":[12,162,216,251,261,292,477],"needed":[13],"especially":[14],"for":[15,44,114,479,529,539,673],"relapsed/refractory":[16],"(R/R)":[17],"patients":[18],"(pts).":[19],"BCL2":[20,40],"is":[21,35,54,128,181,621,640],"an":[22,36,122,151],"anti-apoptotic":[23],"protein":[24],"expressed":[25],"at":[26,643,700],"high":[27,365,671],"levels":[28],"all":[30],"cases":[31],"of":[32,134,177,198,204,211,220,268,276,286,298,344,411,426,444,453,458,469,511,570,582,592,596,601,654,661,703],"CLL.":[33,90,105,117,147],"GDC-0199":[34,45,96,111,135,199,227,244,315,391,402,512,540,555,626,655],"oral,":[37],"highly":[38],"selective":[39],"inhibitor.":[41],"Clinical":[42],"data":[43,93,108,120,327,476],"have":[46,75],"shown":[47],"promising":[48],"anti-CLL":[49],"activity.":[50],"Obinutuzumab":[51,72],"(Gazyva\u00ae,":[52],"Gazyvaro\u2122)":[53],"a":[55,165,194,409,559,650],"Type":[56],"II,":[57],"glycoengineered":[58],"anti-CD20":[59,630],"antibody":[60,631],"that":[61,95,127,637],"has":[62],"increased":[63],"direct":[64],"cell":[65],"death,":[66],"and":[67,73,83,112,132,159,209,271,282,307,353,364,421,464,495,533,544,546,577,594,627,635,649,683,707],"enhanced":[68],"antibody-dependent":[69],"cell-mediated":[70],"cytotoxicity.":[71],"chlorambucil":[74,84],"demonstrated":[76],"improved":[77],"progression-free":[78],"survival":[79],"compared":[80],"to":[81,174,200,218,254,342,406,517,562,574,588,657],"rituximab":[82],"previously":[86,143,708],"untreated":[87,144,709],"pts":[88,115,145,241,291,304,333,385,395,460,471,497,523,525,535,665,699,710],"with":[89,98,116,138,146,150,169,226,461,472],"Also,":[91],"preclinical":[92],"suggest":[94],"combined":[97],"obinutuzumab":[99,113,139,231,514,530,547,593,632],"may":[100],"show":[101],"synergistic":[102],"activity":[103],"Collectively,":[106],"these":[107,323,691],"support":[109],"combining":[110,625],"We":[118],"present":[119],"from":[121,172],"ongoing":[123,575],"phase":[124],"1b":[125],"study":[126,167,337,372,624],"evaluating":[129],"the":[130,202,212,264,294,299,331,383,388,399,427,552,589,622,628,638,644,659,715],"safety":[131],"tolerability":[133],"combination":[137,238,269,571,583,639],"R/R":[141,240,290,303,698],"or":[142,186,230,513,612,670],"Methods":[148],"Pts":[149,215,339],"ECOG":[152],"PS":[153],"\u22641,":[154],"adequate":[155],"marrow,":[156],"hepatic,":[157],"renal":[158],"coagulation":[160],"function":[161],"enrolled":[163,306,386,397,713],"3+3":[166],"design":[168],"cohorts":[170],"ranging":[171],"100":[173,389,553],"600":[175],"mg/day":[176,702],"GDC-0199.":[178,704],"Study":[179,190],"eligibility":[180],"not":[182],"restricted":[183],"by":[184,415],"cytogenetics":[185],"CLL":[187,447,634],"risk":[188,203,347,357,361,366,672],"profile.":[189],"drug":[191],"administration":[192],"incorporates":[193],"gradual":[195,651],"dose":[196,295,527,537,560,652],"ramp-up":[197,653],"reduce":[201,658],"tumor":[205,354],"lysis":[206],"syndrome":[207],"(TLS),":[208],"staggering":[210],"two":[213,221],"agents.":[214],"assigned":[217,341],"one":[219],"dosing":[222,392,403,556],"schedules":[223],"(Figure":[224,507],"1)":[225],"(Schedule":[228,232],"A)":[229],"B)":[233],"introduced":[234],"first.":[235],"After":[236],"completing":[237],"therapy,":[239],"continue":[242,335],"single-agent":[243],"until":[245],"disease":[246],"progression.":[247],"Adverse":[248],"events":[249,312,611],"(AEs)":[250],"graded":[252],"according":[253],"NCI-CTCAE":[255],"v.4":[256],"criteria.":[257],"Dose-limiting":[258],"toxicities":[259],"(DLTs)":[260],"identified":[262,667],"during":[263],"first":[265,428,590,623],"21":[266],"days":[267],"treatment":[270,608],"focus":[272],"on":[273,293,336,350,371,615],"potential":[274],"AEs":[275,504,518],"TLS,":[277,674,679],"infusion":[278,591],"related":[279],"reactions":[280],"(IRRs),":[281],"cytopenias.":[283],"Results":[284],"As":[285],"May":[287],"2014,":[288],"9":[289,332,664,692],"finding":[296],"stage":[297],"study;":[300],"4":[301,324,362,445,480],"additional":[302],"were":[305,340,380,396,519,586,595],"discontinued":[308],"following":[309,408],"clinical":[310,318,686],"TLS":[311,319,346,413,687],"other":[314],"studies.":[316],"No":[317,378,607,685],"was":[320,373,681,688],"observed":[321,381,423,520,689],"pts.":[325,368,430,693],"The":[326,501],"presented":[328],"here":[329],"describe":[330],"who":[334],"treatment.":[338,584],"1":[343,425,468,485,490,549,676],"3":[345,384,429,534,603],"groups":[348],"based":[349],"screening":[351],"ALC":[352],"bulk:":[355],"low":[356],"0":[358],"pts,":[359,363,442],"medium":[360,669],"5":[367,522],"Median":[369],"time":[370],"98":[374],"(range":[375,437,449],"7-252)":[376],"days.":[377],"DLTs":[379],"mg":[390,401,554,564],"cohort.":[393],"Six":[394],"200":[400],"cohort":[404,557],"due":[405,573],"expansion":[407],"DLT":[410],"laboratory":[412,417,678],"(characterized":[414],"asymptomatic":[416],"abnormalities":[418,543],"potassium":[420],"phosphate)":[422],"Baseline":[431],"characteristics":[432],"include:":[433],"median":[434,443],"age":[435],"69":[436],"59-80)":[438],"years,":[439],"6":[440,580],"male":[441],"prior":[446],"1-6),":[450],"beta-2":[451],"microglobulin":[452],"\u22653.5":[454],"mg/L":[455],"7":[457,470],"8":[459],"available":[462,473,478],"data,":[463],"IGVH":[465],"mutation":[466],"data.":[474],"Cytogenetic":[475],"pts:":[481],"none":[482],"had":[483,487,492,498,526,536,558],"del17p,":[484],"pt":[486,491,550],"del":[488,499],"11q,":[489],"trisomy":[493],"12":[494],"2":[496,568],"13q.":[500],"most":[502],"common":[503],"included":[505],"neutropenia":[506],"2).":[508],"Dose":[509,694],"interruptions":[510,528,538],"response":[516],"(2":[524],"only":[531,675],"[IRRs],":[532],"[mainly":[541],"electrolyte":[542],"cytopenias]":[545],"[IRRs]);":[548],"reduction":[561],"50":[563],"per":[565],"day":[566],"after":[567],"cycles":[569,581],"therapy":[572],"neutropenia,":[576],"subsequently":[578],"completed":[579],"IRRs":[585],"limited":[587],"Grade":[597,602],"\u22642.":[598],"One":[599],"event":[600],"pneumonia":[604],"required":[605],"hospitalization.":[606],"emergent":[609],"bleeding":[610],"deaths":[613],"occurred":[614],"study.":[616],"<![if":[617],"!vml]><![endif]>":[618],"Conclusion":[619],"This":[620],"novel":[629],"suggests":[636],"safely":[641],"administered":[642],"doses":[645],"given.":[646],"Prophylactic":[647],"measures":[648],"appear":[656],"incidence":[660],"TLS.":[662],"being":[666],"as":[668],"developed":[677],"which":[680],"transient":[682],"managed.":[684],"escalation":[695],"continues":[696],"400":[701],"Schedule":[705],"B":[706],"will":[711],"be":[712],"near":[716],"future.":[717],"Disclosures":[718],"Flinn:":[719],"Genentech:":[720,746],"Research":[721,729,750],"Funding.":[722,730,751],"Brunvand:Genentech:":[723],"Speakers":[724],"Bureau.":[725],"Hillman:Roche":[726],"Pharmaceuticals:":[727],"Honoraria,":[728],"Jones:Genentech:":[731],"Advisory":[732,747],"Board":[733,748],"Other.":[734],"Lymp:Genentech:":[735],"Employment.":[736,738,740,742],"Elhamy:Genentech:":[737],"Vosganian:Genentech:":[739],"Huang:Genentech:":[741],"Kipps:Cegene,":[743],"Pharacyclics,":[744],"AbbVie,":[745],"Other,":[749]},"counts_by_year":[{"year":2020,"cited_by_count":1},{"year":2019,"cited_by_count":1},{"year":2018,"cited_by_count":1},{"year":2017,"cited_by_count":4},{"year":2016,"cited_by_count":2},{"year":2015,"cited_by_count":15},{"year":2014,"cited_by_count":2}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-07-22T00:00:00"}